The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2022 | Therapeutic challenges for cholangiocarcinoma
Lorenza Rimassa, MD, Humanitas University and IRCCS Humanitas Research Hospital, Milan, Italy, discusses the therapeutic challenges for patients with cholangiocarcinoma. The recent TOPAZ-1 trial (NCT03875235) investigated the use of chemotherapy plus durvalumab in the first-line setting for patients with advanced disease and reported promising data which is likely to be practice changing. There has also been more research into the genetic and molecular characterisation of the disease, which has led to the development of novel targeted therapies. A key challenge moving forward will be to improve access to molecular profiling, so that patients can be given the most suitable targeted therapy. This interview took place at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO WCGIC) 2022 in Barcelona, Spain.
